

Adenosine receptor agonists: synthesis and binding affinity of 2-(aryl)alkylthioadenosine derivatives

Rosaria Volpini, Stefano Costanzi, Catia Lambertucci, Floriana R. Portino, Sara Taffi, Sauro Vittori, Jeff A. Zablocki^o, Karl-Norbert Klotz[§], and Gloria Cristalli*

Dipartimento di Scienze Chimiche, Università di Camerino, I-62032 Camerino (MC), Italy, Department of Bioorganic Chemistry, CV Therapeutics, inc. 3172 Porter Drive, Palo Alto, CA 94304 USA, and

§Institut für Pharmakologie und Toxikologie, Universität of Würzburg, D-97078 Würzburg, Germany

E-mail: gloria.cristalli@unicam.it

**In honor of Prof. Vincenzo Tortorella in the occasion of his “Fuori Ruolo” status
(received 30 Dec 03; accepted 13 Apr 04; published on the web 15 Apr 04)**

Abstract

The synthesis of a new series of 2-(aryl)alkylthio derivatives of N-ethylcarboxamido adenosine (NECA) is described, in comparison with the corresponding derivatives of adenosine. Binding studies (A_1 , A_{2A} , and A_3) and adenylyl cyclase activity (A_{2B}) at human adenosine receptor subtypes stably transfected in Chinese hamster ovary (CHO) cells showed that the 2-(aryl)alkylthioadenosine derivatives are more potent than the corresponding NECA derivatives at A_1 receptors, while the NECA derivatives possess highest affinity at both A_{2A} and A_3 receptors. Thus, the 2-(1-pentyl)thioadenosine (**7**) with a $K_i A_1 = 91$ nM, the 2-phenylethylthioNECA (**18**) with a $K_i A_{2A} = 24$ nM, and the 2-phenylmethylthioadenosine (**11**) with a $K_i A_3 = 68$ nM, could be useful tools to be modified in order to find very potent and selective agonists for the human adenosine receptor subtypes.

Keywords: Adenosine receptors, adenosine receptor agonists, NECA derivatives, adenosine derivatives, (aryl)alkylthioadenosine derivatives

Introduction

Adenosine (Ado, **1**) is a naturally-occurring nucleoside which is reported to modulate a variety of physiological and pathophysiological processes through the interaction with at least for subtypes of a family of cell-surface G-protein-coupled receptors.¹⁻³ These four adenosine receptors (ARs), named A_1 , A_{2A} , A_{2B} , and A_3 , have widespread tissue distribution and are often co-expressed in the same cell type.⁴

The search for potent and selective A_{2A} adenosine receptor agonists has been a target of medicinal chemists, since it is now well known that the coronary vasodilation induced by Ado in different species is mediated by activation of $A_{2A}AR$ and a compound capable of producing coronary vasodilation through activation of $A_{2A}AR$, but that is devoid of A_1 - and A_3 -agonist activity would have advantage over Ado for use in myocardial perfusion imaging studies. Other potential therapeutic applications of selective $A_{2A}AR$ agonists are as anti-aggregatory, anti-inflammatory, anti-psychotic, and anti-Huntington's disease agents.⁵




Figure 1

A series of 2-amino, 2-alkoxy, 2-alkylthio-, 2-alkynyl-, and 2-alkenyl-derivatives of adenosine and N-ethylcarboxamidoadenosine (NECA, **2**)⁶ have been synthesized and tested mainly on different models of rat A_1 and A_{2A} receptor subtypes. From these studies some ligands, such as CGS 21680 (**3**), 2-(1-hexyn-1-yl)-5'-N-ethylcarboxamidoadenosine (HENECA, **4**), and 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)-5'-N-ethylcarboxamidoadenosine (PHPNECA, **5**), showed to possess high A_{2A} affinity combined, in some cases, with good A_{2A} vs A_1 selectivity. More detailed characterization of these ligands at the four cloned human adenosine receptor subtypes revealed that none of the prototypical adenosine receptor agonists exhibits at the same time high affinity and selectivity for the human $A_{2A}AR$ subtype. Both NECA and CGS 21680, which are available as radioligands for this subtype, have lower affinity at human than at rat receptor. The 2-alkynylNECA derivatives HENECA and PHPNECA showed high affinity also at human A_3 receptors. In particular, (*S*)-PHPNECA displayed K_i s in the low nanomolar range at A_1 , A_{2A} , and A_3 subtypes and an EC_{50} of 200 nM at human A_{2B} receptor.⁷

Further structure-activity relationship studies, carried out often only at A_1 and A_{2A} receptor subtypes, had anyhow defined important features of the recognition sites for ARs agonists. The


adenine ring could be substituted at the 2-position improving A_2 AR selectivity and monosubstitution on the N^6 -amino group was tolerated, particularly in the case of A_1 AR. Substitution at both C2 and N^6 generally does not have additive effects on the A_2/A_1 affinity ratio. Combination of substitutions at the 2-position of adenosine and replacing of $-CH_2OH$ with CONHR usually increased A_2 vs A_1 selectivity. On the other hand, the effects on affinity at A_1 and A_2 receptors of concurrent N^6 and $C5'$ modifications, leading to N^6 -substituted N -alkyladenosine-5'-uronamides, resulted to be less than additive.⁷

On this basis the synthesis of a new series of 2-(aryl)alkylthio derivatives of NECA was designed to improve the A_{2A} affinity and selectivity of 2-(aryl)alkylthioadenosines which were reported to possess coronary vasodilating activity^{8,9} and platelet aggregation inhibitory activity.^{10,11}

Chemistry

The synthesis of several 2-(aryl)alkylthio derivatives of adenosine was previously accomplished by the opening-closure method, firstly reported by Kikugawa and Suehido in 1975.¹² Unfortunately, this procedure was unsuccessful in the case of 2-(aryl)alkylthio derivatives of NECA, owing to the basic condition and the high temperature used in the opening step.

Alternatively, a new synthesis has been performed by reacting 2-iodoadenosine (**6**)¹² and 2-iodoNECA (**14**)¹⁴⁻¹⁶ with the appropriate mercaptans in dry DMF at 120 °C using potassium carbonate as a catalyst (Scheme 1 and Table 1).





Scheme 1

Table 1. Preparation of compounds reported in Scheme 1

Compd no.	R	Time (h)	Chromatography solvent	Yield %	mp (°C)
7	CH ₂ CH ₂ CH ₂ CH ₂ C H ₃	20	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (76:14:10)	32	177 dec lit 148-151
8	CH ₂ CH ₂ CH ₂ CH ₂ O H	16	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (72:18:10)	34	88-90
9	cC ₅ H ₉	20	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (80:14:6)	38	213 dec lit 223-225
10	C ₆ H ₅	20	CHCl ₃ -CH ₃ OH (88:12)	40	137-139 lit 125-126
11	CH ₂ C ₆ H ₅	20	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (75:15:10)	63	158 dec lit 158
12	CH ₂ CH ₂ C ₆ H ₅	16	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (77:13:10)	50	205 dec
13	CH ₂ CH ₂ CH ₂ C ₆ H ₅	16	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (78:12:10)	37	92-95
15	CH ₂ CH ₂ CH ₂ CH ₂ C H ₃	36	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (80:10:10)	11	> 270 dec
16	C ₆ H ₅	6	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (80:10:10)	46	122-125
17	CH ₂ C ₆ H ₅	6	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (80:10:10)	78	245 dec
18	CH ₂ CH ₂ C ₆ H ₅	6	CHCl ₃ -CH ₃ OH-cC ₆ H ₁₂ (80:10:10)	57	97-99
19	CH ₂ CH ₂ CH ₂ C ₆ H ₅	16	CHCl ₃ -CH ₃ OH (90:10)	31	185-188

Biological Results and Discussion

All the compounds were evaluated at the human recombinant adenosine receptors, stably transfected into Chinese hamster ovary (CHO) cells, utilizing radioligand binding studies (A₁, A_{2A}, A₃) or adenylyl cyclase activity assay (A_{2B}). Receptor binding affinity was determined using [³H]CCPA (2-chloro-N⁶-cyclopentyladenosine) as radioligand for A₁ receptors, whereas [³H]NECA was used for the A_{2A} and A₃ subtypes (K_i; nM). The relative potencies of these compounds for the A_{2B} subtype were measured by evaluating **TABLE 2**. Affinities of adenosine and NECA derivatives in radioligand binding assays at human A₁, A_{2A}, and A₃ adenosine receptors and effects on adenylyl cyclase activity at human A_{2B} adenosine receptor.



Cpd	R	K _i or EC ₅₀ , nM			
		K _i (A ₁) ^a	K _i (A _{2A}) ^b	EC ₅₀ (A _{2B}) ^c	K _i (A ₃) ^d
2		14	20	2,400	6.2
NECA		(16-28)	(12-35)	(1,900-3,000)	(3.5-11)
3		289	27	89 μM	67
CGS 21680		(232-361)	(12-59)	(56-141)	(50-90)
4		60	6.4	6,100	2.4
HENECA		(50-72)	(3.8-11)	(4,000-9,300)	(2.0-2.9)
5		2.7	3.1	1,100	0.42
PHPNECA		(1.7-4.1)	(2.4-3.9)	(470-2,600)	(0.17-1.0)
7	CH ₃ -(CH ₂) ₄ -	91	1,370	> 100 μM	365
		(83-99)	(993-1,890)		(285-467)
15	CH ₃ -(CH ₂) ₄ -	2,400	4,360	> 100 μM	1,490
		(2,150-2,690)	(3,840-4,950)		(1,270-1,740)
8	HO-(CH ₂) ₄ -	451	3,130	> 100 μM	1,030
		(427-477)	(2,920-3,360)		(837-1,260)
9	cC ₅ H ₉ -	583	418	> 100 μM	843
		(498-682)	(318-685)		(610-1,170)
10	C ₆ H ₅ -	611	990	> 100 μM	669
		(517-722)	(829-1,180)		(563-794)
16	C ₆ H ₅ -	1,010	1,580	> 100 μM	182
		(937-1,100)	(602-4,170)		(144-230)
11	C ₆ H ₅ -CH ₂ -	304	1,510	> 100 μM	68
		(260-354)	1,260-1,810)		(54-85)
17	C ₆ H ₅ -CH ₂ -	480	615	> 100 μM	142
		(400-575)	(368-1,028)		(115-175)
12	C ₆ H ₅ -(CH ₂) ₂ -	99	85	> 100 μM	289
		(85-115)	(39-185)		(191-438)
18	C ₆ H ₅ -(CH ₂) ₂ -	189	24	> 100 μM	86
		(176-203)	(13-44)		(42-173)
13	C ₆ H ₅ -(CH ₂) ₃ -	264	1,640	> 100 μM	568
		(204-342)	(1,500-1,810)		(463-696)
19	C ₆ H ₅ -(CH ₂) ₃ -	466	1,020	> 100 μM	523
		(365-594)	(887-1,180)		(353-774)

^a Displacement of specific [³H]CCPA binding in CHO cells, stably transfected with human recombinant A₁ adenosine receptor, expressed as K_i (nM). ^b Displacement of specific [³H]NECA binding in CHO cells, stably transfected with human recombinant A_{2A} adenosine receptor, expressed as K_i (nM). ^c Measurement of receptor-stimulated adenylyl cyclase activity in CHO cells, stably transfected with human recombinant A_{2B} adenosine receptor, expressed as EC₅₀ (nM). ^d Displacement of specific [³H]NECA binding in CHO cells, stably transfected with human recombinant A₃ adenosine receptor, expressed as K_i (nM).

The receptor-stimulated adenylyl cyclase activity expressed as EC_{50} , nM. NECA (**2**), CGS 21680 (**3**), HENECA (**4**), and PHPNECA (**5**) were reported as reference compounds and the results are shown in Table 2.¹⁷

The reference compound NECA (**2**) showed high affinity at A_1 , A_{2A} , and A_3 receptors and was slightly A_3 selective ($K_i A_1 = 14$ nM, $K_i A_{2A} = 20$ nM, and $K_i A_3 = 6.2$ nM). The potency for A_{2B} receptor, in the low micromolar range, characterized NECA as one of the most active nucleoside at this subtype ($EC_{50} A_{2B} = 2,400$ nM).

The introduction of a 4-(2-carboxyethyl)phenylethylamino group in 2-position of NECA resulted in a compound, CGS 21680 (**3**), which showed decreased affinity and potency at A_1 , A_3 , and A_{2B} adenosine receptor subtypes, while its affinity at the A_{2A} receptors was comparable to that of NECA, hence resulting A_{2A} selective [$K_i A_1 = 290$ nM, $K_i A_{2A} = 27$ nM, $EC_{50} A_{2B} = 89$ μ M, and $K_i A_3 = 67$ nM]. On the other hand, the presence of alkynyl chains in 2-position of NECA (compounds **4** and **5**) resulted in improved A_{2A} affinity compared to NECA and CGS 21680 [HENECA (**4**) and PHPNECA(**5**), $K_i A_{2A} = 6.4$ nM, and $K_i A_{2A} = 3.1$ nM, respectively, vs NECA (**2**) and CGS 21680 (**3**), $K_i A_{2A} = 20$ nM, and $K_i A_{2A} = 27$ nM, respectively]. However, the increasing of A_{2A} affinity was characterized by a contemporary increase of the A_3 affinity, thus the two compounds were slightly A_3 selective as NECA itself. In particular, PHPNECA was found to be a very potent agonist at all adenosine receptor subtypes and one of the most potent A_{2B} agonist reported so far (**5**, $K_i A_1 = 2.7$ nM, $K_i A_{2A} = 3.1$ nM, $EC_{50} A_{2B} = 1,100$ nM, and $K_i A_3 = 0.42$ nM).¹⁸

The 2-(aryl)alkylthio derivatives of adenosine and NECA (compounds **7-13** and **15-19**, respectively) showed affinity at A_1 , A_{2A} , and A_3 adenosine receptor subtypes ranging from low nM to low μ M value. On the contrary, functional data demonstrated that they did not activate the A_{2B} receptors; in fact all the compounds possessed an $EC_{50} A_{2B} > 100$ μ M.

Surprisingly, many compounds (**7**, **8**, **10**, **13**, **19**) showed slight selectivity for the A_1 receptor, a subtype that is known to be activated preferentially by N^6 -substituted adenosine derivatives; the most potent was the 2-(1-pentyl)thioadenosine (**7**) with a $K_i A_1 = 91$ nM. The affinity of the corresponding NECA derivatives **15** decreased at all adenosine receptor subtypes, but these data are to be evaluated with caution because of problems of compound solubility. Substitution of the methyl of the 2-alkylthio chain in compound **7** with an hydroxyl group (compound **8**) decreased affinity at all receptors.

It is worthwhile to note that only three compounds (**9**, **12**, **18**) bound selectively the A_{2A} receptor subtype; thus, both in adenosine and in NECA series, the presence in 2-position of a phenylethylthio substituent was useful in order to improve A_{2A} affinity. In fact, the 2-phenylethylthioadenosine (**12**) and the 2-phenylethylthioNECA (**18**) were the most active A_{2A} agonists with a $K_i A_{2A} = 85$ nM and 24 nM, respectively. Once again, as in the case of CGS 21680, the presence of a particular substituent in the 2-position of NECA led to a compound which showed decreased affinity and potency at both A_1 , A_3 , and A_{2B} adenosine receptor subtypes, while maintaining a A_{2A} affinity comparable to that of NECA, hence resulting in A_{2A} selectivity.

On the other hand, the presence of a longer chain (phenylpropylthio) led to two derivatives, compounds **13** and **19**, which activated preferentially the A₁ receptors, while a shorter chain is better accommodated by the A₃ receptor subtype; in fact the 2-phenylmethylthioadenosine (**11**) and the 2-phenylmethylthioNECA (**17**) were A₃ selective and compounds **11** was the most active A₃ agonist among the two series with a K_i A₃ = 68 nM.

On the contrary, when the phenyl ring is directly linked to the sulfur atom the corresponding adenosine and NECA derivatives (compounds **10** and **16**, respectively) showed a different profile of activity; thus the 2-phenylthioadenosine was slightly A₁ selective, while the corresponding NECA derivatives **16** was A₃ selective.

In conclusion, although the preference for the different adenosine receptor subtypes seems not clearly depend on the nature of the substituent present in the two position, in all cases the 2-(aryl)alkylthioadenosine derivatives are more potent than the corresponding NECA derivatives at A₁ receptors,¹⁹ while the NECA derivatives possess higher affinity in comparison with adenosines at both A_{2A} and A₃ receptors, with the exception of compound **17** which is less active than the corresponding adenosine derivative **11** at A₃ receptor subtypes.

Conclusions

Biological data obtained with the two series of adenosine and NECA derivatives demonstrated that it is possible to modulate the activity at the A₁, A_{2A}, and A₃ adenosine receptor subtypes by introducing different (aryl)alkylthio substituents in the 2-position of adenosine and NECA. In fact the best compounds emerging from this study, 2-(1-pentyl)thioadenosine (**7**) with a K_i A₁ = 91 nM, 2-phenylethylthioNECA (**18**) with a K_i A_{2A} = 24 nM, and the 2-phenylmethylthioadenosine (**11**) with a K_i A₃ = 68 nM, could be useful tools to be modified in order to find very potent and selective agonists for the human adenosine receptor subtypes.

Experimental Section

General Procedures. Melting points were determined with a Büchi apparatus and are uncorrected. ¹H NMR spectra were obtained with Varian VXR 300 MHz spectrometer; δ in ppm, J in Hz. TLC were carried out on pre-coated TLC plates with silica gel 60 F-254 (Merck). For column chromatography, silica gel 60 (Merck) was used. Elemental analyses were determined on Carlo Erba model 1106 analyser and are within $\pm 0.4\%$ of theoretical values.

Preparation of 2-(aryl)alkylthioadenosines (7-13)

A mixture of 2-iodoadenosine (**6**, 0.2 g, 0.51 mmol)¹³ in 5 mL of dry DMF, 2.55 mmol of the appropriate mercaptan, and solid K₂CO₃ (150 mg, 1.05 mmol) was heated in a steel bomb at 120 °C for the time reported in Table 1. The reaction mixture was concentrated *in vacuo* and the residue was chromatographed on a silica gel column eluting with the suitable mixture of solvents (Table 1) to give **7-13** as chromatographically pure white powders.

2-(1-Pentyl)thioadenosine (7). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 0.89 (t, 3H, $J = 6.6$ Hz, CH_2CH_3), 1.35 (m, 4H, $(\text{CH}_2)_2\text{CH}_3$), 1.65 (m, 2H, $\text{CH}_2\text{CH}_2\text{S}$), 3.04 (m, 2H, CH_2S), 3.60 (m, 2H, CH_2-5'), 3.92 (m, 1H, H-4'), 4.13 (m, 1H, H-3'), 4.62 (m, 1H, H-2'), 5.82 (d, 1H, $J = 5.1$ Hz, H-1'), 7.38 (bs, 2H, NH_2), 8.24 (s, 1H, H-8), ^{13}C NMR ($\text{Me}_2\text{SO}-d_6$) δ 14.62 (CH_3), 22.47 (CH_2CH_3), 29.52 ($\text{CH}_2\text{CH}_2\text{CH}_3$), 30.74 ($\text{CH}_2\text{CH}_2\text{S}$), 31.23 (CH_2S), 62.30 (C-5'), 71.16 (C-3'), 73.84 (C-2'), 86.09 (C-4'), 88.02 (C-1'), 117.60 (C-5), 139.51 (C-8), 150.80 (C-4), 156.19 (C-2), 164.47 (C-6). Anal. Calcd. for $\text{C}_{15}\text{H}_{23}\text{N}_5\text{O}_4\text{S}$ (369.4): C, 48.77; H, 6.28; N, 18.96. Found: C, 48.65; H, 6.15; N, 19.08.

2-(1-Butyl-4-hydroxy)thioadenosine (8). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.66 (m, 4H, $(\text{CH}_2)_2\text{CH}_2\text{S}$), 3.11 (m, 2H, CH_2S), 3.54 (m, 4H, CH_2-5' and CH_2OH), 3.92 (m, 1H, H-4'), 4.15 (m, 1H, H-3'), 4.44 (m, 1H, CH_2OH), 4.62 (m, 1H, H-2'), 5.83 (d, $J = 5.1$ Hz, 1H, H-1'), 7.37 (bs, 2H, NH_2), 8.24 (s, 1H, H-8). Anal. Calcd. for $\text{C}_{14}\text{H}_{21}\text{N}_5\text{O}_5\text{S}$ (371.4): C, 45.27; H, 5.70; N, 18.86. Found: C, 45.08; H, 5.39; N, 18.98.

2-Cyclopentylthioadenosine (9). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.60 (m, 6H, cyclopentyl), 2.15 (m, 2H, cyclopentyl), 3.57 (m, 2H, CH_2-5'), 3.92 (m, 2H, H-4' and CHS), 4.12 (m, 1H, H-3'), 4.64 (m, 1H, H-2'), 5.82 (d, $J = 5.9$ Hz, 1H, H-1'), 7.36 (bs, 2H, NH_2), 8.24 (s, 1H, H-8). Anal. Calcd. for $\text{C}_{15}\text{H}_{21}\text{N}_5\text{O}_4\text{S}$ (367.4): C, 49.03; H, 5.76; N, 19.06. Found: C, 48.81; H, 5.46; N, 19.30.

2-Phenylthioadenosine (10). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 3.32 (m, 2H, CH_2-5'), 3.84 (m, 2H, H-4' and H-3'), 4.55 (m, 1H, H-2'), 5.67 (d, $J = 6.1$ Hz, 1H, H-1'), 7.45 (m, 5H, H-Ph and NH_2), 7.60 (m, 2H, H-Ph), 8.24 (s, 1H, H-8). Anal. Calcd. for $\text{C}_{16}\text{H}_{17}\text{N}_5\text{O}_4\text{S}$ (375.4): C, 51.19; H, 4.56; N, 18.66. Found: C, 51.02; H, 4.44; N, 18.75.

2-Benzylthioadenosine (11). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 3.60 (m, 2H, CH_2-5'), 3.93 (m, 1H, H-4'), 4.15 (m, 1H, H-3'), 4.38 (s, 2H, CH_2S), 4.57 (m, 1H, H-2'), 5.88 (d, 1H, $J = 6.1$ Hz, H-1'), 7.30 (m, 3H, H-Ph), 7.46 (m, 4H, H-Ph and NH_2), 8.27 (s, 1H, H-8). Anal. Calcd. for $\text{C}_{17}\text{H}_{19}\text{N}_5\text{O}_4\text{S}$ (389.4): C, 52.43; H, 4.92; N, 17.98. Found: C, 52.34; H, 4.76; N, 18.15.

2-(1-Ethyl-2-phenyl)thioadenosine (12). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 2.99 (m, 2H, CH_2Ph), 3.32 (m, 2H, CH_2S), 3.61 (m, 2H, CH_2-5'), 3.96 (m, 1H, H-4'), 4.15 (m, 1H, H-3'), 4.62 (t, 1H, $J = 5.5$ Hz, H-2'), 5.92 (d, 1H, $J = 6.1$ Hz, H-1'), 7.30 (m, 5H, H-Ph), 7.45 (bs, 2H, NH_2), 8.29 (s, 1H, H-8), ^{13}C NMR ($\text{Me}_2\text{SO}-d_6$) δ 34.35 (CH_2S), 61.46 (C-5'), 70.40 (C-3'), 73.50 (C-2'), 85.41 (C-4'), 87.26 (C-1'), 116.96 (C-5), 126.85 (C-Ph), 128.32 (C-Ph), 129.08 (C-Ph), 138.66 (C-8 and C-Ph), 150.10 (C-4), 155.53 (C-2), 163.19 (C-6). Anal. Calcd. for $\text{C}_{18}\text{H}_{21}\text{N}_5\text{O}_4\text{S}$ (403.5): C, 53.59; H, 5.25; N, 17.36. Found: C, 53.27; H, 5.18; N, 17.48.

2-(3-Phenyl-1-propyl)thioadenosine (13). ^1H NMR ($\text{Me}_2\text{SO}-d_6$) δ 1.98 (m, 2H, $\text{CH}_2\text{CH}_2\text{Ph}$), 2.74 (t, $J = 7.1$ Hz, 2H, CH_2Ph), 3.09 (m, 2H, CH_2S), 3.94 (m, 1H, H-4'), 4.16 (m, 1H, H-3'), 4.63 (m, 1H, H-2'), 5.84 (d, $J = 5.9$ Hz, 1H, H-1'), 7.25 (m, 5H, H-Ph), 7.39 (bs, 2H, NH_2), 8.25 (s, 1H, H-8). Anal. Calcd. for $\text{C}_{19}\text{H}_{23}\text{N}_5\text{O}_4\text{S}$ (417.5): C, 54.66; H, 5.55; N, 16.78. Found: C, 54.48; H, 5.37; N, 16.85.

Preparation of 5-(6-amino-2-(aryl)alkylthiopurin-9-yl)-3,4-dihydroxytetrahydro furan -2-carboxylic acid ethylamides (15-19)

A mixture of 5-(6-amino-2-iodopurin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carboxylic acid ethylamide (2-iodoNECA) (**14**, 0.15 g, 0.35 mmol)¹⁴ in 5 mL of dry DMF, 1.75 mmol of the appropriate mercaptan, and solid K₂CO₃ (150 mg, 1.05 mmol) was heated in a steel bomb at 120 °C for the time reported in Table 1. The reaction mixture was concentrated *in vacuo* and the residue was chromatographed on a silica gel column eluting with the suitable mixture of solvents (Table 1) to give **15-19** as chromatographically pure white powders.

5-(6-Amino-2-pentylsulfanyl-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carboxylic acid ethylamide (15). ¹H NMR (Me₂SO-d₆) δ 0.89 (t, *J* = 6.9 Hz, 3H, (CH₂)₄CH₃), 1.04 (t, *J* = 7.0 Hz, 3H, CH₂CH₃), 1.32 (m, 4H, (CH₂)₂CH₃), 1.67 (m, 2H, CH₂CH₂S), 3.12 (m, 4H, CH₂CH₃ and CH₂S), 4.20 (m, 1H, H-3'), 4.30 (s, 1H, H-4'), 4.72 (m, 1H, H-2'), 5.92 (d, *J* = 7.2 Hz, 1H, H-1'), 7.45 (bs, 2H, NH₂), 8.24 (t, *J* = 5.9 Hz, 1H, NH), 8.33 (s, 1H, H-8). Anal. Calcd. for C₁₇H₂₆N₆O₄S (410.5): C, 49.74; H, 6.38; N, 20.47. Found: C, 49.54; H, 6.38; N, 20.47.

5-(6-Amino-2-phenylsulfanyl-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carboxylic acid ethylamide (16). ¹H NMR (Me₂SO-d₆) δ 1.04 (t, *J* = 7.1 Hz, 3H, CH₂CH₃), 3.18 (m, 2H, CH₂CH₃), 4.12 (m, 1H, H-3'), 4.27 (s, 1H, H-4'), 4.65 (m, 1H, H-2'), 5.82 (d, *J* = 7.2 Hz, 1H, H-1'), 7.45 (m, 5H, H-Ph and NH₂), 7.58 (m, 2H, H-Ph), 8.14 (t, *J* = 5.9 Hz, 1H, NH), 8.37 (s, 1H, H-8). Anal. Calcd. for C₁₈H₂₀N₆O₄S (416.5): C, 51.91; H, 4.84; N, 20.18. Found: C, 51.63; H, 4.56; N, 20.54.

5-(6-Amino-2-benzylsulfanyl-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carboxylic acid ethylamide (17). ¹H NMR (Me₂SO-d₆) δ 1.02 (t, *J* = 6.8 Hz, 3H, CH₂CH₃), 3.19 (m, 2H, CH₂CH₃), 4.18 (m, 1H, H-3'), 4.31 (s, 1H, H-4'), 4.38 (s, 2H, CH₂-S), 4.64 (m, 1H, H-2'), 5.96 (d, *J* = 6.7 Hz, 1H, H-1'), 7.26 (m, 3H, H-Ph), 7.50 (m, 4H, H-Ph and NH₂), 8.27 (t, *J* = 5.4 Hz, 1H, NH), 8.36 (s, 1H, H-8). Anal. Calcd. for C₁₉H₂₂N₆O₄S (430.5) C, 53.01; H, 5.15; N, 19.52. Found: C, 52.75; H, 4.95; N, 19.87.

5-(6-Amino-2-phenethylsulfanyl-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-carboxylic acid ethylamide (18). ¹H NMR (Me₂SO-d₆) δ 1.03 (t, *J* = 7.0 Hz, 3H, CH₂CH₃), 2.97 (m, 2H, CH₂Ph), 3.10-3.50 (m, 4H, CH₂CH₃ and CH₂S), 4.19 (m, 1H, H-3'), 4.32 (s, 1H, H-4'), 4.70 (m, 1H, H-2'), 5.98 (d, *J* = 7.0 Hz, 1H, H-1'), 7.39 (m, 5H, H-Ph), 7.50 (bs, 2H, NH₂), 8.26 (t, *J* = 5.8 Hz, 1H, NH), 8.36 (s, 1H, H-8), ¹³C NMR (Me₂SO-d₆) δ 14.74 (CH₃), 31.87, 33.37, 35.59 (CH₂N, CH₂Ph and CH₂S), 72.47, 73.01 (C-2' and C-3'), 84.17 (C-4'), 86.95 (C-1'), 117.07 (C-5), 126.15 (C-Ph), 128.36 (C-Ph), 128.72 (C-Ph), 139.14, 140.58 (C-Ph and C-8), 150.34 (C-4), 155.64 (C-2), 163.48 (C-6), 169.13 (CO). Anal. Calcd. for C₂₀H₂₄N₆O₄S (444.5): C, 54.04; H, 5.44; N, 18.91. Found: C, 53.79; H, 5.22; N, 19.17.

5-[6-Amino-2-(3-phenylpropylsulfanyl)purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-carboxylic acid ethylamide (19). ¹H NMR (Me₂SO-d₆) δ 1.05 (t, *J* = 7.1 Hz, 3H, CH₂CH₃), 1.97 (m, 2H, CH₂CH₂Ph), 2.73 (m, 2H, CH₂Ph), 2.97-3.34 (m, 4H, CH₂CH₃ and CH₂S), 4.23 (m, 1H, H-3'), 4.32 (s, 1H, H-4'), 4.62 (m, 1H, H-2'), 5.94 (d, *J* = 7.2 Hz, 1H, H-1'), 7.28 (m, 5H, H-Ph), 7.45 (bs, 2H, NH₂), 8.25 (t, *J* = 5.7 Hz, 1H, NH), 8.34 (s, 1H, H-8). Anal. Calcd. for C₂₁H₂₆N₆O₄S (458.5): C, 55.01; H, 5.72; N, 18.33. Found: C, 54.65; H, 5.49; N, 18.66.

Biological studies

Cloning of the human adenosine receptors, stable transfection of cells, cell culture, membrane preparation, radioligand binding, and adenylyl cyclase activity have been fully described elsewhere.²⁰ Briefly, all human subtypes were stably transfected into Chinese hamster ovary (CHO) cells in order to be able to study their pharmacological profile in an identical cellular background utilizing radioligand binding studies (A_1 , A_{2A} , A_3) or adenylyl cyclase activity assays (A_{2B}).

Receptor binding affinity was determined using [3 H]CCPA as radioligand at A_1 receptors, whereas [3 H]NECA was used at A_{2A} and A_3 subtypes. The procedure was performed as described previously. Due to the lack of a suitable radioligand the relative potency of agonists at A_{2B} adenosine receptors was determined in adenylyl cyclase experiments. The procedure was carried out as described previously with minor modifications.²⁰

Acknowledgements

Supported by a grant from the Ministry of Research (COFIN, Grant no. 200061553, 2002) and by the European Community (COST action no. D13/0009/00).

References

1. *Adenosine Receptors: Medicinal Chemistry, Pharmacology and Therapeutic Applications*; Cristalli, G.; Volpini R. Eds; *Curr. Topics Med. Chem.* **2003**, *3*, pp 355-469.
2. Yan, L.; Burbiel, J. C.; Maab, A.; Mueller, C. E. *Expert Opin. Emerging Drugs* **2003**, *8*, 537.
3. Jacobson, M. A. *Expert Opin. Ther. Patents* **2002**, *12*, 489.
4. Fredholm, B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. *Pharmacol. Rev.* **2001**, *53*, 527.
5. Fredholm, B. B.; Cunha, R. A.; Svenningsson, P. *Curr. Topics Med. Chem.* **2003**, *3*, 413.
6. Ha, S. B.; Nair, V. *Tetrahedron Lett.* **1996**, *37*, 1567.
7. Cristalli, G.; Lambertucci, C.; Taffi, S.; Vittori, S.; Volpini, R. *Curr. Topics Med. Chem.* **2003**, *3*, 387.
8. Maguire, H.; Nobbs, D. M.; Einstein, R.; Middleton, J. C. *J. Med. Chem.* **1971**, *14*, 415.
9. Marumoto, R.; Yoshioka, Y.; Osamu, M.; Shunsuke, S.; Imai, K.-I.; Kawazoe, K.; Honjo, M. *Chem. Pharm. Bull.* **1975**, *23*, 759.
10. Kikugawa, K.; Suehiro, H.; Ichino, M. *J. Med. Chem.* **1973**, *16*, 1381.
11. Kikugawa, K.; Suehiro, H.; Yanase, R.; Aoki, A. *Chem. Pharm. Bull.* **1977**, *25*, 1969.
12. Kikugawa, K.; Suehiro, H. *J. Carb. Nucl. Nucl.* **1975**, *2*, 159.
13. Nair, V.; Richardson, S. G. *Synthesis* **1982**, 670.

14. Cristalli, G.; Eleuteri, A.; Vittori, S.; Volpini, R.; Lohse, M. J.; Klotz, K.-N. *J. Med. Chem.* **1992**, *35*, 2363.
15. Cristalli, G.; Volpini, R.; Vittori, S.; Camaioni, E.; Monopoli, A.; Conti, A.; Dionisotti, S.; Zocchi, C.; Ongini, E. *J. Med. Chem.* **1994**, *37*, 1720.
16. Cristalli, G.; Volpini, R.; Vittori, S.; Camaioni, E.; Monopoli, A.; Conti, A.; Dionisotti, S.; Zocchi, C.; Ongini, E. *J. Med. Chem.* **1995**, *37*, 1720.
17. Klotz, K.-N.; Camaioni, E.; Volpini, R.; Kachler, S.; Vittori, S.; Cristalli, G. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1999**, *360*, 103.
18. Camaioni, E.; Di Francesco, E.; Vittori, S.; Volpini, R.; Cristalli, G. *Bioorg & Med Chem.* **1997**, *5*, 2267.
19. Volpini, R.; Costanzi, S.; Lambertucci, C.; Taffi, S.; Vittori, S.; Klotz, K.-N.; Cristalli, G. *J. Med. Chem.* **2002**, *45*, 3271.
20. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, B.; Kull, B.; Fredholm, B. B.; Lohse, M. J. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1998**, *357*, 1.